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Bioprosthetic mitral valve thrombosis in a patient in sinus rhythm after
the radiofrequency maze procedure
Nakao Masakazu, MD, Lim See Lim, MBBS, FRCS, FAMS, and Chua Yeow Leng, MBBS, FRCS, FAMS, Singapore
Bioprosthetic valves are the preferred option for mitralvalve replacement in the elderly because there is a lowrisk of thromboembolic complications compared withmechanical valves. Current consensus is that long-term
anticoagulation can be avoided in patients with bioprosthetic valve
replacement because postoperative thromboembolic risk after
3 months is extremely low.1 Once anticoagulation is withdrawn,
thrombosis causing bioprosthetic valve dysfunction is extremely
rare.
Clinical Summary
A 69-year-old man with a history of stroke 14 years before surgical
intervention underwent mitral valve replacement with a 31-mm
Hancock II porcine bioprosthesis (Medtronic, Inc, Minneapolis,
Minn) and the radiofrequency maze procedure for severe mitral
regurgitation and chronic atrial fibrillation. He was started on
warfarin, and the international normalized ratio was kept within a
therapeutic range of 2.0 to 2.5. Postoperative transthoracic echo-
cardiography (TTE) showed normal bioprosthetic valve function
with a mean mitral pressure gradient (PG) of 4.0 mm Hg.
Warfarin was discontinued at 1½ years postoperatively because
there was no recurrence of atrial fibrillation on follow-up electro-
cardiography and 24-hour Holter tests. Aspirin was continued for
minor coronary artery disease. TTE before cessation of warfarin
confirmed normal mitral valve function with a mean PG of 6.0
mm Hg. Ratio of early filling velocity to atrial contraction velocity
(E/A ratio) was 1.58, implying active atrial contraction. Left ven-
tricular ejection fraction (LVEF) was 62%. Left atrial diameter
was 6.0 cm.
One month after warfarin was stopped, the patient was admitted
with fever, shortness of breath, and loss of appetite for 3 days.
Blood culture was sterile. Chest radiography revealed acute pul-
monary edema. TTE demonstrated severe mitral stenosis with a
mean mitral PG of 24 mm Hg and pressure half-time (PHT) of
187 ms. The mitral valve leaflets were thickened, and leaflet
motion was restricted. There was no change in LVEF or left atrial
diameter. The E/A ratio was 1.4. Transesophageal echocardiogra-
phy (TEE) confirmed the findings on TTE. No discrete intracardiac
thrombus was visualized. Valve thickness on TEE was 6.5 mm
(Figures 1 and 2).
Intravenous unfractionated heparin and diuretics were started,
and warfarin was resumed. Heparin was withdrawn when the
international normalized ratio reached the therapeutic range. He-
matologic work-up did not reveal a hypercoagulable state.
A repeat TTE 1 week later showed a decreased mean mitral PG
of 11 mm Hg. PHT had also decreased to 107 ms. Two weeks after
treatment was commenced, TTE demonstrated normal mitral bio-
prosthetic valve function with a mean mitral PG of 6.2 mm Hg and
a PHT of 114 ms. Three months after discharge, TEE revealed a
mean mitral valve PG of 4.0 mm Hg and a valve thickness of 1.2 mm.
The patient was maintained on warfarin and was well on
follow-up 6 months later.
Discussion
Bioprosthetic mitral valve thrombosis is a rare cause of prosthetic
valve dysfunction postoperatively. Low cardiac output,1 large left
atrium,1 prior history of thromboembolic events,1 low transvalvu-
lar flow caused by atrial fibrillation,2,3 and abnormality in blood
rheology4 are most commonly cited as predisposing factors.
In this case there were no obvious risk factors for thrombosis:
LVEF was normal, the left atrium was only mildly enlarged, and
there was no hypercoagulable diathesis, although the patient did
have a history of stroke 14 years before the operation. Surgical
intervention had also successfully been used to treat the problem of
atrial fibrillation, and he had been in sinus rhythm for 1½ years.
His E/A ratio was 1.58 before warfarin was withdrawn. He was
also taking aspirin, and it has been reported that aspirin alone can
reduce the risk of postoperative thromboembolic complications after
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ment showing grossly thickened mitral valve.
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bioprosthetic valve implantation in the mitral position.1 Radiofre-
quency maze lesion lines were unlikely to be a source leading to
propagation onto the valve leaflets because there were no intra-
atrial clots and thrombus was laminar along all the valve leaflets.
Intravenous heparin was started in this patient with a plan to
commence thrombolytic therapy if heparin alone was ineffective.
Although thrombolytic therapy is an established first-line treat-
ment, this patient responded to heparin anticoagulation followed
by warfarin. Several studies have reported good resolution of
bioprosthetic thrombus after conventional anticoagulation.2-5 Con-
curring with these studies, we had a favorable result after 1 week
of heparin and subsequent warfarinization.
Clinically significant bioprosthetic valve thrombosis is rare,
although the reported incidence in the study by Oliver and col-
leagues5 is 6.2%. It should be considered a possible cause of valve
dysfunction when there is increasing transvalvular pressure gradi-
ent after anticoagulation is terminated. Treatment with conven-
tional anticoagulation is unavoidable in such a setting.
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A case of mitral valve plasty for Libman–Sacks
endocarditis mimicking a cardiac tumor
Shingo Taguchi, MD, Kazuhiro Hashimoto, MD, Yoshimasa Sakamoto, MD,
Hiroshi Okuyama, MD, and Shinichi Ishii, MD, Tokyo, Japan
We report a patient with multiple cerebral infarcts inwhom 2-dimensional echocardiography showed alarge mass attached to the anterior mitral leafletand chordae. An intracardiac tumor was diag-
nosed, and surgical intervention was performed. The resected mass
proved to be a Lib-
man–Sacks vegeta-
tion on microscopy.
This is frequently
found in patients with systemic lupus erythematosus (SLE).
Unique echocardiographic and intracardiac findings are reported
here with the technique of mitral valve plasty.
Clinical Summary
A 34-year-old woman was admitted after the sudden onset of
aphasia associated with mild hemiplegia of her left arm and leg.
She had been receiving treatment for SLE for 9 years, but the
disease had been inactive, and she had been well, except for
numbness in her left hand, at 7 months before this episode. Her
medications were an H2 blocker and an oral steroid (5 mg/d
prednisolone). Admission laboratory tests revealed normal serum
chemistry, normal C-reactive protein (CRP) levels, no anemia, and
mild thrombocytopenia (the platelet count was 55  103/L).
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Figure 2. Doppler scan showing increased mean mitral pressure
gradient (mean mitral pressure gradient 24 mm Hg).
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